In this Phase I/II influenza vaccine trial, AMR Clinical was selected to lead participant enrollment across 11 of 22 U.S. sites. AMR Clinical sites enrolled 50% of all U.S. participants, maintained a 98% retention rate, and completed enrollment a month ahead of schedule. Leveraging centralized project delivery and internal monitoring, AMR minimized delays and aligned enrollment closely with 2020 U.S. Census diversity targets.
Read this case study to explore how AMR Clinical delivered:
- 4-week early completion and ~25% estimated sponsor cost savings
- Daily compliance monitoring and rapid greenlight activation
- Diversity-aligned enrollment and high participant retention